Tandem Diabetes Care Inc. [TNDM] EVP & Chief Operating Officer makes an insider purchase of 10,097 shares worth 0.66 million.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Tandem Diabetes Care Inc. shares valued at $656,515 were sold by BERGER DAVID B on Jun 08. At $65.02 per share, BERGER DAVID B sold 10,097 shares. The insider’s holdings dropped to 2,457 shares worth approximately $0.14 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, BLICKENSTAFF KIM D sold 10,762 shares, netting a total of over 999,897 in proceeds. Following the sale of shares at $92.91 each, the insider now holds 205,190 shares.

Before that, Sheridan John F had added 2,500 shares to its account. In a trade valued at $174,750, the PRESIDENT & CEO bought Tandem Diabetes Care Inc. shares for $69.90 each. Upon closing the transaction, the insider’s holdings increased to 2,500 shares, worth approximately $0.59 million.

Analysts at Wells Fargo upgraded the stock from ‘”an Equal weight”‘ to ‘”an Overweight”‘ outlook in a report released in mid January. Earlier on May 25, 2021, Barclays initiated its rating. Their recommendation was “an Underweight” for TNDM stock.

Analyzing TNDM’s Price Performance

On Thursday, Tandem Diabetes Care Inc. [NASDAQ: TNDM] plunged -15.04% to $58.60. The stock’s lowest price that day was $56.745, but it reached a high of $62.12 in the same session. During the last five days, there has been a drop of approximately -12.33%. Over the course of the year, Tandem Diabetes Care Inc. shares have dropped approximately -61.07%. Shares of the company reached a 52-week high of $150.64 on 01/03/22 and a 52-week low of $52.08 on 07/13/22. A 50-day SMA is recorded $61.39, while a 200-day SMA reached $104.61. Nevertheless, trading volume fell to 2.72 million shares from 0.7 million shares the previous day.

Support And Resistance Levels for Tandem Diabetes Care Inc. (TNDM)

According to the 24-hour chart, there is a support level at 56.19, which, if violated, would cause prices to drop to 53.78. In the upper region, resistance lies at 61.56. The next price resistance is at 64.53. RSI (Relative Strength Index) is 42.84 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.18, which suggests the price will increase in the coming days. Percent R is at 71.67%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Tandem Diabetes Care Inc. subject to short interest?

Stocks of Tandem Diabetes Care Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.6 million shares to 4.5 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 3.9 million shares. A jump of 13.33% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.69 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.69.

Which companies own the most shares of Tandem Diabetes Care Inc. (TNDM)?

According to The Vanguard Group, Inc. filings, the company currently owns 6,221,343 shares, which is about 9.73% of the total TNDM shares outstanding. The investor’s shares have appreciated by 154,337 from its previous 13-F filing of 6067006.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $318,318,138. Fidelity Management & Research Co acquire a 5.91% interest valued at $282.37 million while Capital Research & Management Co sold a -580,877 stake. A total of 135,344 shares of Tandem Diabetes Care Inc. were sold by Invesco Advisers, Inc. during the quarter, and 59,778 were bought by SSgA Funds Management, Inc. In its current portfolio, Champlain Investment Partners LLC holds 1,541,325 shares valued at $91.23 million.

In terms of Tandem Diabetes Care Inc. share price expectations, FactSet research, analysts set an average price target of $99.33 in the next 12 months, up nearly 31.94% from the previous closing price of $68.97. Analysts anticipate Tandem Diabetes Care Inc. stock to reach $200.00 by 2022, with the lowest price target being $72.00. In spite of this, 13 analysts ranked Tandem Diabetes Care Inc. stock as an Overweight at the end of 2022. On December 15, 2020, Wells Fargo assigned a price target of “an Equal weight” to the stock and downgraded coverage with a $105.

LEAVE A REPLY

Please enter your comment!
Please enter your name here